Clinical Trial Update: CPG 7909 in Patients Wih Stage IV Renal Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored CPG 7909 was evaluated in a Phase 1/2 trial for stage IV renal cell carcinoma and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CPG 7909 (CpG 7909)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED